BioLineRx Ltd.

Equities

BLRX

IL0011015182

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 07:54:08 23/05/2024 pm IST			5-day change	1st Jan Change
16.1 ^ILa	+2.55%		0.00%	-57.85%

17/04	BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	CI
10/04	BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	CI

BioLineRx Ltd. Approves Appointment of Kesselman & Kesselman as Independent Registered Public Accounting Firm for the Year Ending December 31, 2023

August 09, 2023 at 02:55 am IST

BioLineRx Ltd. approved the appointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the Company's independent registered public accounting firm for the year ending December 31, 2023, at the AGM held on August 7, 2023.

Latest news about BioLineRx Ltd.

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17/04	CI
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10/04	CI
BioLineRx Shares Fall After $6 Million Registered Direct Offering	01/04	MT
Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024	26/03
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	04/03	CI
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer	28/02	CI
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?	16/02	CI
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	21/12	CI
BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director	12/12	CI
Transcript : BioLineRx Ltd., Q3 2023 Earnings Call, Nov 20, 2023	20/11
BioLineRx Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20/11	CI
BioLineRx Signs License Agreement With GloriaBio for Multiple Myeloma Drug	12/23/12	MT
Biolinerx Ltd. Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment	12/23/12	CI
BioLineRx Ltd. announced that it has received $14.6 million in funding	12/23/12	CI
BioLineRx Says Pilot Phase of Combination Trial With Motixafortide in First-Line Pancreatic Cancer Yields 'Encouraging' Data	28/23/28	MT
Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer	28/23/28	CI
HC Wainwright Raises BioLineRx's Price Target to $21 From $19, Maintains Buy Rating	15/23/15	MT
Transcript : BioLineRx Ltd. - Special Call	12/23/12
BioLineRx Shares Climb 22% After FDA Approves Aphexda With Filgrastim	11/23/11	DJ
BioLineRx Gets FDA Approval for Aphexda With Filgrastim	11/23/11	DJ
BioLineRx Ltd Announces FDA Approval of APHEXDA? (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma	11/23/11	CI
Transcript : BioLineRx Ltd., Q2 2023 Earnings Call, Aug 30, 2023	30/23/30
BioLineRx Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30	CI
Biolinerx Ltd. Enters into License Agreement with Hong Seng Technology Limited and Guangzhou Gloria Biosciences Co., Ltd	30/23/30	CI

Chart BioLineRx Ltd.

Duration

Period

More charts

Company Profile

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for BioLineRx Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOLINERX LTD.	-57.85%	5.26Cr
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.65%	11TCr
BIONTECH SE	-6.20%	2.39TCr
ARGENX SE	-3.49%	2.16TCr
GENMAB A/S	-9.63%	1.9TCr
BEIGENE, LTD.	-13.41%	1.63TCr
WUXI APPTEC CO., LTD.	-40.50%	1.7TCr
NEUROCRINE BIOSCIENCES, INC.	+6.64%	1.41TCr
SAREPTA THERAPEUTICS, INC.	+31.84%	1.2TCr

Bio Therapeutic Drugs